OncotelicTherapeutics, Inc. announced the appointment of Dr. Fatih Uckun as its Chief Medical Officer. Dr. Uckun will be responsible for execution of internal company led registrational trials. Prior to joining Oncotelic, Dr. Uckun served as Chief Medical Officer and Chief Scientific Officer of Reven Pharmaceuticals (from 2020 to 2022), Chief Medical Officer of Ares Pharmaceuticals (from 2017 to 2022).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0376 USD | +1.21% | +1.62% | -1.83% |
1st Jan change | Capi. | |
---|---|---|
-1.83% | 15.07M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- OTLC Stock
- News Oncotelic Therapeutics, Inc.
- Oncotelic Therapeutics, Inc. Appoints Fatih Uckun as Chief Medical Officer